The safety and efficacy of glaucoma medication in the pediatric population

Journal of Pediatric Ophthalmology and Strabismus

Volumn 46, Issue 1, 2009, Pages 12-18

  Coppens, Greet ^a   Stalmans, Ingeborg ^a   Zeyen, Thierry ^a   Casteels, Ingele ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BICARBONATE; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; CHLORIDE; CLONIDINE; CREATININE; DORZOLAMIDE; ELECTROLYTE; LATANOPROST; METIPRANOLOL; NITROGEN; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST; UREA; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; EYE DROPS; PROSTAGLANDIN F;

ADJUVANT THERAPY; ANGIONEUROTIC EDEMA; APNEA; ASTHENIA; ASTHMA; BICARBONATE BLOOD LEVEL; BITTER TASTE; BLEPHARITIS; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; BURNING SENSATION; CHLORIDE BLOOD LEVEL; CHOROID DISEASE; CLINICAL TRIAL; COMA; CONJUNCTIVA DISEASE; CONJUNCTIVITIS; CORNEA DISEASE; CORNEA EDEMA; CREATININE BLOOD LEVEL; DEPRESSION; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EPISTAXIS; ERYTHEMA; EYE INFLAMMATION; EYE IRRITATION; EYE TOXICITY; FATIGUE; GLAUCOMA; GLAUCOMA SURGERY; GROWTH RETARDATION; HEART RATE; HUMAN; HYPEREMIA; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; HYPOTENSION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; IRITIS; LACRIMATION; LOW LEVEL LASER THERAPY; METABOLIC ACIDOSIS; MONOTHERAPY; MUSCLE HYPOTONIA; MYOPIA; NAUSEA; NEUROTOXICITY; OPEN ANGLE GLAUCOMA; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PRURITUS; PUNCTATE KERATITIS; RECOMMENDED DRUG DOSE; RESPIRATION DEPRESSION; RESPIRATORY FUNCTION; RETINA MACULA EDEMA; REVIEW; RHINITIS; SEDATION; SIDE EFFECT; SINUSITIS; SKIN DISCOLORATION; SLEEP DISORDER; SOMNOLENCE; SWEATING; TACHYPHYLAXIS; UREA NITROGEN BLOOD LEVEL; UROLITHIASIS; URTICARIA; UVEITIS; CHILD; INFANT; PRESCHOOL CHILD; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; CHILD; CHILD, PRESCHOOL; GLAUCOMA; HUMANS; INFANT; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; TREATMENT OUTCOME;

EID: 61549129607     PISSN: 01913913     EISSN: None     Source Type: Journal    
DOI: 10.3928/01913913-20090101-05     Document Type: Review

References (35)

1. Ho CL, Walton DS. Management of childhood glaucoma. Curr Opin Ophthalmol. 2004;15:460-464.
2. Hoskins HD Jr, Hetherington J Jr, Magee SD, Naykhin R, Migliazzo CV. Clinical experience with timolol in childhood glaucoma. Arch Ophthalmol. 1985;103:1163-1165.
3. Wallace DK, Steinkuller PG. Ocular medications in children. Clin Pediatr. 1998;37:645-652.
4. Papadopoulos M, Khaw PT. Advances in the management of pediatric glaucoma. Eye. 2007;21:1319-1325.
5. Maris PJ Jr, Mandal AK, Netland PA. Medical therapy of pediatric glaucoma and glaucoma in pregnancy. Ophthalmol Clin North Am. 2005;18:461-468.
6. Passo MS, Palmer EA, Van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology. 1984;91:1361-1363.
7. McMahon CD, Hetherington JJ, Hoskins JH, Shaffer RN. Timolol and pediatric glaucomas. Ophthalmology. 1981;88:249-252.
8. Ott EZ, Mills MD, Arango S, Getson AJ, Assaid CA, Adamsons IA. A randomized trial assessing dorzolamide in patients with glaucoma who are younger than 6 years. Arch Ophthalmol. 2005;123:1177-1186.
9. Sabri K, Levin AV. The additive effect of topical dorzolamide and systemic acetazolamide in pediatric glaucoma. J AAPOS. 2006;10:464-468.
10. Portellos M, Buckley EG, Freedman SF. Topical versus oral carbonic anhydrase inhibitor therapy for pediatric glaucoma. J AAPOS. 1998;2:43-47.
11. Maren TH. The development of topical carbonic anhydrase inhibitors. J Glaucoma. 1995;4:49-62.
12. Moore W, Nischal KK. Pharmacologic management of glaucoma in childhood. Pediatr Drugs. 2007;9:71-79.
13. Futagi Y, Otani K, Abe J. Growth suppression in children receiving acetazolamide with antiepileptic drugs. Pediatr Neurol. 1996;15:323-326.
14. Moffett BS, Moffett TI, Dickerson HA. Acetazolamide therapy for hypochloremic metabolic alkalosis in pediatric patients with heart disease. Am J Ther. 2007;14:331-335.
15. Morris S, Geh V, Nischal K, Sahi S, Ahmed MA. Topical dorzolamide and metabolic acidosis in a neonate. Br J Ophthalmol. 2003;87:1052-1053.
16. Sirbat D. What should we think? Should Diamox® and pilocarpine continue to be prescribed? [article in French] J Fr Ophtalmol. 30:72-73.
17. Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS. 2001;5:281-284.
18. Al-Shahwan SM, Al-Torbak AA, Turkmani SM, Al-Omran MM, Al-Jadaan IM, Edward DP. Side-effect profile of brimonidine tartrate in children. Ophthalmology. 2005;112:2143.
19. Montero-de-Espinosa I, Márquez-de-Aracena R, Morales C. Ocular hypertension in children treated with brimonidine 0.2%: a clinical study [article in Spanish]. Arch Soc Esp Oftalmol. 2006;81:155-159.
20. Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr. 2004;43:99-101.
21. Daubert GP. Is brimonidine ophthalmic a safe therapy for infants? J Clin Pharm Ther. 2006;31:289-292.
22. Bowman RJ, Cope J, Nischal KK. Ocular and systemic side effects of brimonidine 0,2% eye drops (Alphagan) in children. Eye. 2004;18:24-26.
23. Berlin RJ, Lee UT, Samples JR, et al. Ophthalmic drops causing coma in an infant. J Pediatr. 2001;138:441-443.
24. Detry-Morel M, Dutrieux C. Treatment of glaucoma with brimonidine (Alphagan 0.2%) [article in French]. J Fr Ophtalmol. 2000;23:763-769.
25. Enyedi LB, Freedman SF. Latanoprost for the treatment of pediatric glaucoma. Surv Ophthalmol. 2002;47:S129-S132.
26. Urban B, Bakunowicz Lazarczyk A, Mrugacz M, Ozieblo Kupczyk M. The effectiveness of latanoprost for the treatment of pediatric glaucoma. Klin Oczna. 2004;106:243-244.
27. Enyedi LB, Freedman SF, Buckley EG. The effectiveness of latanoprost for the treatment of pediatric glaucoma. J AAPOS. 1999;3:33-39.
28. Ong T, Chia A, Nischal KK. Latanoprost in port wine stain related paediatric glaucoma. Br J Ophthalmol. 2003;87:1091-1093.
29. Yang CB, Freedman SF, Myers JS, Buckley EG, Herndon LW, Allingham RR. Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome. Am J Ophthalmol. 1998;126:600-602.
30. Altuna JC, Greenfield DS, Wand M, et al. Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects. J Glaucoma. 1999;8:199-203.
31. Lindsey JD, Kashiwagi K, Kashiwagi F, Weinreb RN. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv Ophthalmol. 1997;41(suppl):S53-S59.
32. Simmons ST, Cioffi GA, Gross RL, et al. Basic and Clinical Science Course, Section 10: Glaucoma. San Francisco: American Academy of Ophthalmology; 2007-2008.
33. Phelps CD. The pathogenesis of glaucoma in Sturge-Weber syndrome. Ophthalmology. 1978;85:276-286.
34. Kirwan C, O'Keefe M. Pediatric aphakic glaucoma. Acta Ophthalmol Scand. 2006;84:734-739.
35. Elgin U, Batman A, Berker N, Ilhan B. The comparison of eyelash lengthening effect of latanoprost therapy in adults and children. Eur J Ophthalmol. 2006;16:247-250.